The ICB therapies, such as PD-1 Ab, have shown impressive clinical benefits in many types of cancer; however, most patients with cancer do not respond to ICB therapy due to lack of T cell infiltration at tumor sites (74). Here, PDCD1 is linked to neoplasm.